<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084721</url>
  </required_header>
  <id_info>
    <org_study_id>RP 02-24</org_study_id>
    <secondary_id>RPCI-RP-0224</secondary_id>
    <nct_id>NCT00084721</nct_id>
  </id_info>
  <brief_title>Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I Study of Irinotecan in Combination With Fixed Dose Celecoxib in Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor&#xD;
      cells by blocking the enzymes necessary for their growth. Giving irinotecan with celecoxib&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when&#xD;
      given with celecoxib in treating patients with unresectable or metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of irinotecan when administered with celecoxib in&#xD;
           patients with unresectable or metastatic colorectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the dose-limiting toxic effects and non-dose-limiting toxic effects of this&#xD;
           regimen in these patients.&#xD;
&#xD;
        -  Determine the incidence and intensity of diarrhea and myelotoxicity in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine any responses in patients treated with this regimen.&#xD;
&#xD;
        -  Determine potential mechanisms for irinotecan-induced diarrhea and protective effects of&#xD;
           celecoxib on diarrhea prevention in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of irinotecan. Patients are assigned to 1 of 2&#xD;
      treatment groups.&#xD;
&#xD;
        -  Group I: Patients receive a fixed dose of irinotecan IV over 90 minutes on days 1, 8,&#xD;
           15, and 22 and oral celecoxib twice daily on days 10-42. Courses repeat every 42 days in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Group II: Patients receive irinotecan as in group I at escalating doses and oral&#xD;
           celecoxib twice daily on days 0-42. Treatment continues as in group I.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-30 patients (9 for group I, 9-21 for group II) will be&#xD;
      accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">2</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Diarrhea</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal cancer&#xD;
&#xD;
               -  Metastatic or unresectable disease&#xD;
&#xD;
          -  Failed first-line or second-line therapy OR recurred after receiving&#xD;
             fluorouracil-based adjuvant chemotherapy&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  No Gilbert's disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to receive oral medications&#xD;
&#xD;
          -  No prior inflammatory bowel disease&#xD;
&#xD;
          -  No active ulcer disease or gastritis&#xD;
&#xD;
          -  No contraindications for sigmoidoscopy&#xD;
&#xD;
          -  No active colostomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to irinotecan, celecoxib, sulfonamides, or other study agents&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior different chemotherapy regimens, including adjuvant therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy of more than 3,000 cGy&#xD;
&#xD;
          -  No prior radiotherapy to extended marrow-generating fields&#xD;
&#xD;
          -  No prior abdomino-pelvic irradiation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior abdominoperineal resection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior cyclo-oxygenase-2 (COX-2) inhibitors&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other anticancer therapy&#xD;
&#xD;
          -  No other concurrent COX-2 inhibitors&#xD;
&#xD;
               -  Low-dose aspirin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diarrhea</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

